Q32 Bio Inc Dossier - Source-backed chat

Q32 Bio Inc

QTTBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.08

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.25Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $245.6M

Enterprise Value $139.3M

Shares Outstanding 29.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Q32 Bio Inc. (NASDAQ: QTTB) is a clinical-stage biotechnology company uniquely positioned to disrupt the autoimmune and inflammatory disease landscape, specifically alopecia areata (AA). The company's lead asset, bempikibart (ADX-914), is a first-in-class fully human monoclonal antibody targeting IL-7Rα, which dual-blocks both the IL-7 and TSLP pathways. Unlike existing JAK inhibitors that require continuous dosing and carry black-box warnings, bempikibart has demonstrated a potential 'remittive effect' in its Phase 2a Part A trial, with patients showing deepening and sustained hair regrowth up to 55 weeks (7 months post-dosing). Backed by a robust balance sheet bolstered by a recent $55 million private placement in May 2026 and non-dilutive cash from the sale of ADX-097 to Akebia Therapeutics, Q32 Bio possesses a cash runway extending into the first half of 2028. With the highly anticipated 36-week topline data from the SIGNAL-AA Part B trial expected in mid-2026, the stock presents an asymmetric risk-reward profile for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$38.75

High · most bullish analyst$66.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0015%

The SIGNAL-AA Part B topline data is underwhelming or fails to show a statistically significant improvement over placebo, or safety concerns emerge regarding T-cell depletion. The remittive effect observed in Part A is not replicated in the larger cohort, severely damaging bempikibart's competitive profile against approved JAK inhibitors. Strategic options for the complement platform fail to materialize, and Akebia encounters development delays with ADX-097, deferring milestone payments. The company is forced to restructure or raise highly dilutive capital, depressing the stock price.

Base CaseCentral scenario

$13.5060%

The SIGNAL-AA Part B trial delivers positive topline results consistent with Part A, showing steady, durable hair regrowth and confirming bempikibart's favorable safety profile. The FDA supports advancement into pivotal Phase 3 trials under its Fast Track designation. Q32 Bio maintains its disciplined cost structure, and its cash runway remains secure into 1H 2028, supported by the $55 million private placement and scheduled milestone payments from Akebia. The stock trades up toward consensus analyst targets as clinical de-risking attracts institutional interest.

Bull CaseUpside scenario

$20.0025%

The SIGNAL-AA Part B 36-week topline data meets or exceeds expectations, demonstrating a SALT score reduction of >30% and a high proportion of patients achieving SALT ≤20 with a clean safety profile. Bempikibart's unique dual-pathway inhibition is validated as a disease-modifying therapy with a durable remittive effect, positioning it as a superior, safer alternative to JAK inhibitors. Q32 Bio successfully out-licenses its remaining complement platform (ADX-096) for upfront cash, and Akebia rapidly advances ADX-097, triggering early milestone payments. The company transitions smoothly into pivotal Phase 3 trials with a cash runway extending beyond 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Mechanism of Action: Bempikibart dual-blocks IL-7 and TSLP pathways, targeting the root cause of T-cell-mediated hair follicle destruction without the systemic safety risks of JAK inhibitors.
Potential Remittive Effect: Clinical data from SIGNAL-AA Part A showed deepening hair regrowth responses up to 55 weeks, suggesting patients may achieve long-term remission after stopping treatment.
Strong Financial Position: A cash runway extending into 1H 2028, anchored by $50.8 million in cash (as of March 31, 2026), a $55 million private placement in May 2026, and non-dilutive milestone eligibility from Akebia.
FDA Fast Track Designation: Facilitates rolling review and frequent communication with the FDA, accelerating the path to potential commercialization.

Key Investment Risks

Clinical Development Risk: The upcoming SIGNAL-AA Part B topline data may fail to replicate the efficacy or safety profile observed in earlier cohorts.
Single-Asset Concentration: Following the sale of ADX-097 and the pausing of the renal basket trial, Q32 Bio's valuation is heavily dependent on the clinical success of bempikibart.
Competitive Landscape: The alopecia areata market is highly competitive, with established oral JAK inhibitors (e.g., Pfizer's ritlecitinib, Eli Lilly's baricitinib) already commercialized.
Execution Risk: Potential delays in clinical trial enrollment, regulatory filings, or manufacturing scale-up for Phase 3 trials.

Thesis Invalidation Triggers

Failure of the SIGNAL-AA Part B trial to meet its primary efficacy endpoints of SALT score reduction at 36 weeks.
Emergence of serious adverse events (SAEs) related to bempikibart that compromise its safety profile.
Termination or significant delay of the ADX-097 development program by Akebia Therapeutics, eliminating anticipated milestone payments.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.